Advertisement

Advertisement

Letters to the Editor

COVID-19

Is Estrogen Protective Against COVID-19?

Avrum Z. Bluming, MD, MACP  /  May 25, 2020

Reports suggest that the severity of coronavirus infection may be significantly more pronounced in men than in women.1 Studies have demonstrated that estrogen reduces both influenza virus replication in human female nasal epithelial cells2 and moderates the cytokine storm in murine models of this in...

COVID-19

Unnecessary Barrier to Blood Donation for British Nationals?

The ASCO Post  /  April 25, 2020

I read with great interest Jo Cavallo’s article “Maintaining Blood Donations During the COVID-19 Pandemic”. My wife and I have been British residents in the United States for over 6 years and are frustrated that we cannot donate blood, especially during this raging global COVID-19 pandemic, when blo...

Reflections on a Career in Hematology/Oncology

Ronald E. Turk, MD  /  March 10, 2020

I am a retired 82-year-old Hematologist/Oncologist who reads The ASCO Post regularly. I am writing to share some brief thoughts with the authors of two articles in the February 10, 2020 issue. First, I would address the article, A Hopeful Look Ahead in Oncology, written by Dan L. Longo, MD, MACP. ...

Breast Cancer

Postmenopausal Estrogen and Risk of Breast Cancer: What Is the Real Story?

Avrum Bluming  /  February 25, 2020

I am responding to an article in the January 25, 2020, issue of The ASCO Post on the conclusion of the 19-year follow-up on the Women’s Health Initiative (WHI) presented by Rowan T. Chlebowski, MD, PhD, at the 2019 San Antonio Breast Cancer Symposium: Postmenopausal estrogen administration does not ...

Issues in Oncology

‘We Need an Index of Biologic Aging’

Ernest Greenberg, MD  /  April 15, 2012

As a retired elderly (soon to be 83-year-old) oncologist, I read the recent article on the subject of geriatric oncology, in the March 15 issue of The ASCO Post, with great interest ("Moving the Field of Geriatric Oncology Forward," by Stuart M. Lichtman, MD, FACP, FASCO.) This was particularly so b...

Issues in Oncology

Physicians Should Lead by Example to Combat the Obesity Epidemic

Damien Hansra, MD  /  November 25, 2019

American patients are suffering from an obesity crisis, where it is estimated that 300,000 deaths per year are due to obesity.1 The obesity trend is predicted to worsen, where it is projected that 85% of U.S. adults will be overweight or obese by 2030.2 Consequently, obesity-related illnesses are on...

Issues in Oncology

Being an Expert Witness in a Legal Proceeding: A Learning Experience

Michael B. Van Scoy-Mosher, MD  /  October 10, 2019

I read with great interest and appreciation the Law and Ethics in Oncology column, “Should You Become an Expert Witness in a Legal Proceeding? Here Are the Pros and Cons,” by Thaddeus Pope, JD, PhD (August 25, 2019, issue of The ASCO Post). I am an oncologist and have been an expert witness in a var...

Breast Cancer

Evidence Lacking That Denosumab Alters the Course of Breast Cancer

The ASCO Post  /  June 25, 2019

I am writing to provide personal context to my column on adjuvant denosumab or bisphosphonates for resected breast cancer, which appears on page 52 in this issue of The ASCO Post. I have been upset since 2013 that adjuvant zoledronate has been recommended for women with breast cancer onset after ag...

Well-Deserved Attention on Lung Cancer Screening

Giuseppe Del Priore, MD  /  April 25, 2019

SCREENING FOR LUNG CANCER among high-risk groups deserves the attention that Steven E. Vogl, MD, brought to it in his column At Microphone 1 in the February 10 issue of The ASCO Post. Subspecialist oncologists are not always attuned to the needs of their patients outside of their own specialty.1 Eve...

Pain Management
Issues in Oncology
Supportive Care

Opioid Toolkit: Helping Nebraskan Hospitals to Provide Appropriate Pain Management

The ASCO Post  /  April 10, 2019

As the opioid epidemic continues to sweep the United States, providers across Nebraska are facing the challenge of determining the appropriateness of pain treatment options that both meet the needs of the patients and fall within nationally published guidelines. A recent report published by the Nat...

Skin Cancer

LETTER TO THE EDITOR: Adjuvant Therapy in Cutaneous Melanoma: The Need for a New Approach

E. George Elias, MD, PhD  /  June 15, 2011

Melanoma of the skin remains a fatal disease, and its incidence continues to rise, mostly in young adults during their prime. Surgery remains the most effective therapeutic modality, but patients’ survival depends on the stage of the disease at the time of diagnosis. Various therapeutic agents have ...

Issues in Oncology

Pathways Reconsidered: Let’s Not Stop ‘Thinking Outside the Box’

Stephen C. Fox, MD, FACP  /  September 15, 2011

I read “Are Clinical Pathways Inevitable in Oncology’s Future?” (The ASCO Post, July 15, 2011) including Lesli Lord’s interview with great interest and agree with most everything said in the article. However, I do want to make one comment: There is no specialty for which the 80/20 rule applies more ...

Breast Cancer

LETTER TO THE EDITOR: Treating Cancer or Fear?

Gilbert A. Lawrence, MD  /  October 15, 2011

I read the article by Deb Stewart, “Acting on Fear” (The ASCO Post, August 15, 2011, page 1) with interest, disappointment, and empathy. “Acting on fear” in cancer treatment generally, and particularly in breast cancer, is not uncommon. Hence, I was most interested in the article’s major thrust, as...

Issues in Oncology

LETTER TO THE EDITOR: ‘Unrealistic Optimism’ or Losing Sight of the Forest for the Trees?

Stephen G. Chandler, MD  /  October 15, 2011

The article: “Unrealistic Optimism Poses Ethical Challenges, May Affect Informed Consent Process” (The ASCO Post, September 1, 2011, page 35) seems to be delving into a subject with an intent that is unclear. I agree fully with Dr. Jimmie Holland that discrimination between “optimism” and “unrealis...

Cost of Care

Cost of Cancer Therapy: The Elephant in the Room?

Michael J Kraut, MD  /  March 15, 2012

I am distressed by your coverage of innovative therapies, such as dual HER2 blockade (see The ASCO Post, January 1, 2012, and Supplement to February 15, 2012), without mentioning that these therapies will never be cost-effective given the current pricing of the agents involved. If we wish to maintai...

Health-Care Policy

Letter to the Editor: Patient Protection and Affordable Care Act Reconsidered

Calvin J. Dykstra, MD  /  May 1, 2012

I read with interest the front-page interview of Dr. Ezekiel Emanuel by Jo Cavallo in the December 15, 2011, issue of The ASCO Post. Dr. Emanuel may have had some of the most prestigious positions in all of medicine, but his opinion of the Affordable Care Act is completely misguided. This legislatio...

Health-Care Policy

Physicians Need to Be Involved in Reducing Costs

Thomas J. Lester, MD  /  June 15, 2012

I am so proud of ASCO for participating in the American Board of Internal Medicine Foundation’s Choosing Wisely campaign (see The ASCO Post, May 1, page 19; and page 75 of this issue). I am the Associate Medical Director for a 280-physician multispecialty group in the Hudson Valley of New York, whi...

Regional Disparities in Cancer Mortality

Nengliang Yao, MS  /  June 15, 2012

I was interested to see an article about the continuing declines in cancer death rates featured in the April 15 issue of The ASCO Post (page 94), as I have just published a paper on breast cancer mortality rates.1 Although overall breast cancer mortality rates have decreased significantly, a much sm...

Palliative Care

The Semantics of Palliative Care

Khalid L. Rehman, MD, FACP  /  June 15, 2012

The interview with Thomas J. Smith, MD (The ASCO Post, April 15, 2012), the lead author of the ASCO Palliative Care Provisional Clinical Opinion, was timely. However, it left many clinical terms and issues unclear. A significant percentage of modern medicine, including cancer care, is palliative. C...

Prostate Cancer

Prostate Cancer Management: A Day Late and A Dollar Short?

Gilbert A. Lawrence, MD, DMRT, FRCR  /  July 1, 2012

In the May 15 issue, The ASCO Post reported on the relative cost-effectiveness of approaches to treating localized prostate cancer (“Advances in Prostate Cancer Accompanied by Ongoing Debates,” page 1). The article analyzed an important scientific paper presented at both urology and radiation oncolo...

Prostate Cancer

Letter to the Editor: More Thoughts on PSA

James Mohler, MD, and Donald L. Trump, MD  /  September 15, 2012

An article that appeared in the August 15 issue of The ASCO Post (“Rethinking the Role of PSA Screening in Public Health”) contains false statements about the discovery of prostate-specific antigen (PSA) and its effectiveness as a test for early detection of prostate cancer. Contrary to what’s repo...

Prostate Cancer

Letter to the Editor: Dr. Ablin’s Reply

Richard J. Ablin, PhD, DSc (Hon)  /  September 15, 2012

Given my explanation and widely publicized opinion on the improper use of the prostate-specific antigen (PSA) test for screening asymptomatic men for prostate cancer—most recently expressed in a feature article in The ASCO Post (August 15, 2012)—I was pleased to read that Drs. James Mohler and Donal...

Issues in Oncology

LETTER TO THE EDITOR: Individualism in Clinical Decision-making

Jonathan Schwartz, MD  /  October 15, 2012

I found a statement by Dr. Peter Bach in the August 15, 2012, issue of The ASCO Post (in the article, “As Conflicting Guidelines Evolve, Experts Continue to Debate the Merits of Cancer Screening”) very troubling. To wit: There’s a cognitive dissonance between the practice of evidence-based medicine...

Letter to the Editor: Origins of PSA Testing: The Conversation Continues

T. Ming Chu, PhD, DSc  /  November 15, 2012

As Drs. James Mohler and Donald Trump noted in their September 15 letter to The ASCO Post (“More Thoughts on PSA,” 3[14]:2, 2012), Richard Ablin, PhD, discovered a “prostate-specific antigen” of unknown properties, but his PSA is not the antigen in the PSA test we know today. Since Dr. Ablin has no...

Updates on Ruxolitinib from ASCO and ASH 2012, including Long-term Survival Data

Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Ronald Hoffman, MD, Jason Gotlib, MD, Rami Komrokji, MD, and Hagop M. Kantarjian, MD  /  December 15, 2012

Ruxolitinib (Jakafi), a novel, oral JAK1 and JAK2 inhibitor, was approved by the FDA on November 16, 2011 for patients with intermediate- or high-risk myelofibrosis. The approval was based on its efficacy in reducing spleen size and improving disease-related burdensome symptoms. In the brief In the ...

The ‘True’ History of the Discovery of Prostate-specific Antigen

William J. Catalona, MD  /  December 15, 2012

I am frequently asked about the “true” history of prostate-specific antigen (PSA). As PSA has become more important, a controversy about its discovery has increased. I lived through much of this history and have known many of the “players.” Here are the relevant facts, as I believe them to be true. ...

Health-care Crisis Reconsidered

Jonathan Schwartz, MD  /  December 15, 2012

As an oncologist in private practice, I usually read with great interest the many articles in The ASCO Post on issues regarding the politics of oncology practice. These articles deal with the major topics of the day, ranging from the high cost of oncologic care to shortages of generic drugs, to alle...

The Language of Cancer

Gopal N. Gupta, MD  /  December 15, 2012

I am a member of ASCO and read with interest your piece entitled “The Language of Cancer” in the October 15, 2012, issue of The ASCO Post. By way of introduction, I am an attending physician specializing in urologic oncology at Loyola University Medical Center. My group recently published an articl...

Cost of Care
Health-Care Policy

More Thoughts on Rationing Cancer Care

Gilbert A. Lawrence, MD, DMRT, FRCR  /  February 1, 2013

I read the article about “The Ethics of Rationing Cancer Care” with interest (The ASCO Post, Dec 15, 2012). The issue of rationing (or rational) care has likely been debated since Hippocrates. Yet the topic has become a focus of acute interest with the current fiscal crises facing countries around t...

Health-Care Policy

Another Perspective on Accountable Care Organizations

Jonathan Schwartz, MD  /  April 15, 2013

I read with great interest Dr. Richard Boxer’s editorial on accountable care organizations in the January 15 issue of The ASCO Post. Much of what he says is unfortunately true. There are several points that I would like to make, however. First of all, Dr. Boxer states that the “principle that defin...

Issues in Oncology

Conflicts of Interest

Laurence Baker, DO  /  April 15, 2013

In looking at a recent issue of The ASCO Post, I noted that expert opinions from specialists were published alongside a number of clinical reports. Below each opinion was a disclosure statement, often saying that the expert had no conflict of interest to report. While I do not know each of these ind...

Disclosure: Appropriate or Not?

M. Steven Piver, MD  /  April 15, 2013

The ASCO Post is an outstanding publication that I always look forward to reading. I also understand there are policies and rules to be followed, particularly regarding conflicts of interest and disclosures from contributors. I am writing in regard to “Cancer Has Made Me A Better Doctor,” by David P...

Breast Cancer
Issues in Oncology

Mammography Screening and DCIS

Judith Malmgren, MS, PhD  /  May 15, 2013

I would like to suggest that ASCO take a proactive approach to the treatment of ductal carcinoma in situ (DCIS) and the problem it presents to the oncology community. There has been and continues to be heated debate around the value of mammography screening because of “overdiagnosis,” which in my op...

More Recollections on Emil 'Tom' Frei III, MD

Larry Weisenthal, MD, PhD  /  June 10, 2013

I have read with interest the recent tributes to Emil “Tom” Frei III, MD, who passed away in April. I was backstage at the ASCO Annual Meeting in 1981, when Dr. Frei was giving his Karnofsky acceptance address. I had a slide presentation at the combined ASCO/American Association for Cancer Research ...

Breast Cancer

Conversations with Breast Cancer Patients

Ernest Greenberg, MD  /  July 25, 2013

I am a retired oncologist, previously an attending physician at Memorial Sloan-Kettering Cancer Center, with a professional lifetime experience in caring for patients with all stages of breast cancer, and now I am a regular reader of The ASCO Post. In recent months there have been several articles ...

Global Cancer Care

Clinical Trials for Patients in Africa

Ogidiagba Louis Efe, MBBS  /  July 25, 2013

Thank you very much for The ASCO Post Evening News,* which ensures I don’t miss anything that happened at the ASCO 2013 meeting. Due to financial constraints I could not attend the ASCO Annual Meeting in Chicago. My comment is that pharmaceutical companies should extend their oncology drug trials ...

Issues in Oncology

‘Medicalizing’ Physician-assisted Suicide

Mitchell Garrison, MD  /  July 25, 2013

It was with regret that I read the article and commentary on physician-assisted suicide in the June 10 issue of The ASCO Post (“Death with Dignity Program at Seattle Cancer Care Alliance,” by Matthew Stenger, and “One Cancer Center’s Approach to Death with Dignity,” by Frederick R. Appelbaum, MD). ...

Head and Neck Cancer

Support Group Offers Resources for Patients with Oral/Head and Neck Cancer

Chris Leonardis  /  August 15, 2013

I am the Outreach Administrator/Newsletter Editor at Support for People with Oral and Head and Neck Cancer (SPOHNC). SPOHNC is a national nonprofit organization involved in the development of support programs. As such, it can have an enormous positive impact on meeting the psychosocial needs of pati...

Prostate Cancer

Seeking Clarity on the PSA Story

Richard J. Ablin, PhD, DSc (Hon)  /  August 15, 2013

My feature interview in the August 15, 2012, issue of The ASCO Post, entitled “Rethinking the Role of PSA Screening in Public Health”1 drew swift reaction from well-known figures in the prostate cancer field. The subsequent Letters to the Editor, three in all, constituted a two-pronged attack. They ...

Lymphoma

Déjà Vu Redux: Lessons from the SWOG-8516 Study in Aggressive Lymphomas

Wyndham H. Wilson, MD, PhD  /  August 15, 2013

Joseph M. Connors, MD, authored a commentary in the June 25 issue of The ASCO Post inspired by a recent New England Journal of Medicine publication on dose-adjusted EPOCH-R chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) for primary mediastinal B-cell ...

Leukemia

Clinical Trials, Crossover, and Clinical Equipoise: A Patient's Perspective

Bob Levis  /  September 15, 2013

I am writing with regard to two articles on the ethical imperative of clinical equipoise written by Susan O’Brien, MD, and Stephen J. Schuster, MD, and published recently in The ASCO Post.1,2 I was a victim of Pharmacyclics’ policies during one of their randomized ibrutinib trials (PCI-32765) conduc...

Leukemia

Clinical Trials, Crossover, and Clinical Equipoise: An Advocate's Perspective

Karl Schwartz  /  September 15, 2013

In a previous issue of The ASCO Post, Dr. Susan O’Brien wrote, “It is my understanding that the FDA strongly opposed allowing crossover [in the RESONATE trial]. I presume that is because the FDA also wants to see if there is a survival advantage.”1 The lack of crossover seems a valid concern to me ...

Leukemia

Pharmacyclics' Reply

Danelle James, MD, MS, and Jesse McGreivy, MD  /  September 15, 2013

We acknowledge the letters submitted to The ASCO Post from a patient advocate and a chronic lymphocytic leukemia (CLL) patient enrolled on the RESONATE study (PCYC-1112-CA). At Pharmacyclics, we are committed to adhering to high scientific and ethical standards as we strive to develop novel therapi...

Leukemia

FDA on CLL Drug Approval and Expanded Access

R. Angelo de Claro, MD, Edvardas Kaminskas, MD, Ann Farrell, MD, and Richard Pazdur, MD  /  September 15, 2013

The ASCO Post article, “Ibrutinib CLL Trial: Where is the Equipoise?” published in May 2013, inaccurately conveyed that the Food and Drug Administration (FDA) requires an improvement in overall survival for chronic lymphocytic leukemia (CLL) drug approval and opposes allowing crossover in the RESONA...

'Doing Nothing' Is Not an Option

Khalid Rehman, MD, FACP  /  October 15, 2013

I applaud The ASCO Post for continuing to raise awareness about futile medical care at the close of life with the recent publication of a commentary by Dr. Chandrakanth Are (“A Great Privilege to Die Beneath an Open Sky,” The ASCO Post, September 15, 2013, page 1). I would suggest, however, that we...

To Die Beneath an Open Sky

Elizabeth D. Simmons, MD  /  October 15, 2013

I read the essay by Chandrakanth Are, MBBS, FRCS, FACS, published recently in The ASCO Post and found it both thoughtful and compelling (“A Great Privilege to Die Beneath an Open Sky,” The ASCO Post, September 15, 2013, page 1). Dr. Are made one statement with which I take exception, however, and th...

Breast Cancer

Platinum-Based Treatment of Triple-Negative Breast Cancer

Larry Weisenthal, MD, PhD  /  October 15, 2013

The last issue of The ASCO Post reports encouraging results with platinum-based treatment of triple-negative breast cancer (September 15, 2013). We predicted these findings 4 years ago in a presentation at the 2009 Breast Symposium.1 We compared the activity of a series of agents (platinum, taxane,...

Skin Cancer

Intralesional Cytokine Therapy in Cutaneous Melanoma: A Call for Clinical Trials

E. George Elias, MD, PhD  /  November 1, 2013

Cutaneous melanomas are mostly an immunogenic group of tumors, but they are also heterogeneous. Therefore, therapeutic specificity and autogenetic approaches are essential to secure beneficial results. The objective of sentinel lymph node biopsy, at the time of diagnosis, is to identify patients wi...

Perception of Bias

Richard Herrmann, MD  /  December 15, 2013

I am a veteran member of ASCO (> 33 years) and a regular reader of The ASCO Post Evening News, which usually provides very interesting information. A recent issue contained an article about a review presented by Tony Reid, MD, PhD, at a Best of ASCO meeting on “Important Findings in Metastatic Co...

The ASCO Post Replies

James O. Armitage, MD, Editor-in-Chief and Cara H. Glynn, Editorial Director  /  December 15, 2013

We appreciate Dr. Herrmann’s concerns in regard to conflict of interest. The ASCO Post makes every effort to present news and data in an objective and fair manner. Often we invite an independent expert in a particular area to share his or her perspective to lend more insight to a report.  We recogn...

Advertisement

Advertisement



Advertisement